Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare: Three induction chemotherapy schedules (namely ADE versus ADE or DA in combination with Mylotarg, given in course 1). Two doses of Mylotarg (3mg/m2 vs 6mg/m2) given on day 1 of course 1. A total of three versus four courses of treatment in total, comparing MACE versus MACE/MidAc.in consolidation. FLT3 inhibitor CEP-701 for patients with a FLT3 mutation mTOR inhibition in patients who lack a FLT3 mutation, and who are not high risk, and who do not have Core Binding Factor Leukaemia In high risk patients to compare novel treatments, initially Daunorubicin/Clofarabine vs standard FLAG-Ida. To assess the prognostic value of minimal residual disease monitoring for patient overall survival, and the value of this information on clinical outcome.
Critère d'inclusion
- Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome